Last reviewed · How we verify
atazanavir boosted with ritonavir
atazanavir boosted with ritonavir is a Protease inhibitor Small molecule drug developed by ANRS, Emerging Infectious Diseases. It is currently in Phase 3 development for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV.
Atazanavir is a protease inhibitor that blocks the protease enzyme in HIV, preventing the virus from replicating.
Atazanavir is a protease inhibitor that blocks the protease enzyme in HIV, preventing the virus from replicating. Used for Treatment of HIV-1 infection in adults and children, Prevention of mother-to-child transmission of HIV.
At a glance
| Generic name | atazanavir boosted with ritonavir |
|---|---|
| Sponsor | ANRS, Emerging Infectious Diseases |
| Drug class | Protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious diseases |
| Phase | Phase 3 |
Mechanism of action
Atazanavir works by binding to the protease enzyme, which is essential for the maturation of viral particles. By inhibiting this enzyme, atazanavir prevents the virus from replicating and reduces the viral load in the body. Ritonavir, a booster, is used in combination to increase the levels of atazanavir in the body.
Approved indications
- Treatment of HIV-1 infection in adults and children
- Prevention of mother-to-child transmission of HIV
Common side effects
- Nausea
- Diarrhea
- Fatigue
- Headache
- Rash
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV (PHASE4)
- Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia (NA)
- Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
- Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- atazanavir boosted with ritonavir CI brief — competitive landscape report
- atazanavir boosted with ritonavir updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI
Frequently asked questions about atazanavir boosted with ritonavir
What is atazanavir boosted with ritonavir?
How does atazanavir boosted with ritonavir work?
What is atazanavir boosted with ritonavir used for?
Who makes atazanavir boosted with ritonavir?
What drug class is atazanavir boosted with ritonavir in?
What development phase is atazanavir boosted with ritonavir in?
What are the side effects of atazanavir boosted with ritonavir?
What does atazanavir boosted with ritonavir target?
Related
- Drug class: All Protease inhibitor drugs
- Target: All drugs targeting HIV protease
- Manufacturer: ANRS, Emerging Infectious Diseases — full pipeline
- Therapeutic area: All drugs in Infectious diseases
- Indication: Drugs for Treatment of HIV-1 infection in adults and children
- Indication: Drugs for Prevention of mother-to-child transmission of HIV
- Compare: atazanavir boosted with ritonavir vs similar drugs
- Pricing: atazanavir boosted with ritonavir cost, discount & access